profile_id,first_name,last_name,sub_title,profile_picture,background_image,profile_type,entity_urn,object_urn,birth_date,summary,location,premium,influencer,treasury_media,languages,industry,education,patents,awards,certifications,organizations,projects,publications,courses,test_scores,position_groups,volunteer_experiences,skills,network_info,related_profiles,contact_info
susan-van-boxtel-08140b8,Susan,van Boxtel,Sr. Advisor Foreign Investments Health & Food / Team Manager at East Netherlands Development Agency (Oost NL) Invest-in-Holland Network,https://media.licdn.com/dms/image/D4E03AQEZLqU6m8woTw/profile-displayphoto-shrink_800_800/0/1664695128808?e=1697673600&v=beta&t=AGBg33B8teNS35131lc5LUbaxTmokuYsO-7cJs8h8_0,https://media.licdn.com/dms/image/C4D16AQFghHomcurBnA/profile-displaybackgroundimage-shrink_350_1400/0/1645135898512?e=1697673600&v=beta&t=D0MnNfdUMYk7cy6CxKUX5J56GjW4GoJUbhXEWEIieCk,personal,ACoAAAF7-qEB6oQFzRHFlEbrz48Ct4f5_IY6_PY,24902305,,"Working for the Regional Economic Development Agency, I support international companies towards successful establisment in the (East) Netherlands. Focusing on companies to strengthen the sectors Life Sciences & Health, and Agri-Food. 

Since 10 years, I enjoy working in business-government relations: 
Previously I advised Dutch companies and universities on international R&D collaborations while working as innovation advisor at the Dutch Embassy in Singapore. Before working for Dutch governmental organisations, I was trained as medical biologist and working as preclinical researcher for large pharmaceutical companies in the Netherlands and in Singapore for ten years.

I contribute to the economic mission of the East Netherlands Development Agency (Oost NL).  Oost NL catalyses economic growth through (i) organising public-private innovation programmes (ii) funding of startups and scaleups (iii) advising and supporting international companies to successfully establish or expand in the (East) Netherlands.
Oost NL continuously works towards a futureproof economy, by: 
(i)	Accelerate implementation of new technologies and expertise by regional startups and SME; 
(ii)	Invest in growth of innovative startups and scaleups; 
(iii)	Strengthen international competitiveness of regional companies; 
(iv)	Advice international companies towards successful establishment in the (East) Netherlands.

Invitation: please contact me for confidential, free-of-charge services; exploring the opportunities for international expansion to the Netherlands: susan.vanboxtel@oostnl.nl
#investinholland
www.oostnl.com","{'country': 'Netherlands', 'short': 'Apeldoorn, Gelderland', 'city': 'Apeldoorn', 'state': 'Gelderland', 'default': 'Apeldoorn, Gelderland, Netherlands'}",False,False,[],"{'primary_locale': {'country': 'US', 'language': 'en'}, 'supported_locales': [{'country': 'US', 'language': 'en'}], 'profile_languages': []}",Government Relations,"[{'date': {'start': {'month': None, 'day': None, 'year': 2004}, 'end': {'month': None, 'day': None, 'year': 2007}}, 'school': {'name': 'Radboud University', 'logo': 'https://media.licdn.com/dms/image/C4E0BAQHgdni-2v0psQ/company-logo_400_400/0/1670846116863?e=1700697600&v=beta&t=vgJeC3CA6j7MZM594LPJ9niyV2uONRQXRNwcseFWVLI', 'url': 'https://www.linkedin.com/school/radboud-university-nijmegen/'}, 'degree_name': 'MSc', 'field_of_study': 'Biology'}, {'date': {'start': {'month': None, 'day': None, 'year': 1999}, 'end': {'month': None, 'day': None, 'year': 2002}}, 'school': {'name': 'HU University of Applied Sciences Utrecht (Hogeschool Utrecht)', 'logo': 'https://media.licdn.com/dms/image/C4D0BAQE5MUvxbWmHLg/company-logo_400_400/0/1616758673383?e=1700697600&v=beta&t=BFc-IvBmnsS59MQBYUDwDMeWNDtcmWNsNk3Q7Kc1jBM', 'url': 'https://www.linkedin.com/school/hogeschool-utrecht/'}, 'degree_name': 'Bsc', 'field_of_study': 'Biomedical research'}, {'date': {'start': {'month': None, 'day': None, 'year': 1988}, 'end': {'month': None, 'day': None, 'year': 1994}}, 'school': {'name': 'Ommelander College Appingedam', 'logo': None, 'url': None}, 'degree_name': 'Atheneum', 'field_of_study': 'Secondary Education and Teaching'}]",[],[],[],[],[],"[{'name': 'Early detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI', 'publisher': 'Cancer Medicine', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/?term=MRI+cancer+hentze+boxtel', 'date': {'month': None, 'day': None, 'year': 2014}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Susan', 'last_name': 'van Boxtel', 'name': None, 'headline': 'Sr. Advisor Foreign Investments Health & Food / Team Manager at East Netherlands Development Agency (Oost NL) Invest-in-Holland Network'}, {'type': 'standardizedContributor', 'first_name': 'Hannes', 'last_name': 'Hentze', 'name': None, 'headline': 'Translational R&D  I PhD & INSEAD Global Executive MBA'}, {'type': 'standardizedContributor', 'first_name': 'Reshmi', 'last_name': 'Rajendran', 'name': None, 'headline': 'Head of Innovation and R&D | Open Innovation | Entrepreneurship | Precision Nutrition  | Sustainability  | Agtech'}, {'type': 'standardizedContributor', 'first_name': 'Torsten', 'last_name': 'Reese', 'name': None, 'headline': 'Group Leader MRI at Schering-Plough'}, {'type': 'standardizedContributor', 'first_name': 'Brian', 'last_name': 'Henry', 'name': None, 'headline': 'Executive Director and Site Lead, Quantitative Biosciences at MSD'}]}, {'name': 'Chronic and acute anti-angiogenic treatment effects detected by arterial spin labeling in mouse tumor', 'publisher': 'Tumor Therapy Response: Preclinical & Clinical', 'url': 'http://www.ismrm.org/12/Session04.htm', 'date': {'month': None, 'day': None, 'year': 2012}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Susan', 'last_name': 'van Boxtel', 'name': None, 'headline': 'Sr. Advisor Foreign Investments Health & Food / Team Manager at East Netherlands Development Agency (Oost NL) Invest-in-Holland Network'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Reshmi Rajendran (first author)', 'headline': None}]}, {'name': 'PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.', 'publisher': 'J Immunother. 2012 Feb-Mar;35(2):169-78.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22306905', 'date': {'month': None, 'day': None, 'year': 2012}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Susan', 'last_name': 'van Boxtel', 'name': None, 'headline': 'Sr. Advisor Foreign Investments Health & Food / Team Manager at East Netherlands Development Agency (Oost NL) Invest-in-Holland Network'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Dulos J (1st author), Boots AM, et al.', 'headline': None}]}]",[],[],"[{'company': {'id': 52827, 'name': 'Oost NL', 'logo': 'https://media.licdn.com/dms/image/C4D0BAQHNUX4BdFZQJQ/company-logo_400_400/0/1519856856386?e=1700697600&v=beta&t=0aXtBolbMwx1H-Q0Y_i6UJdERbl5hcC6edO87sp5q4w', 'url': 'https://www.linkedin.com/company/oostnl/', 'employees': {'start': 51, 'end': 200}}, 'date': {'start': {'month': 4, 'day': None, 'year': 2018}, 'end': {'month': None, 'day': None, 'year': None}}, 'profile_positions': [{'location': 'Apeldoorn Area, Netherlands', 'date': {'start': {'month': 2, 'day': None, 'year': 2019}, 'end': {'month': None, 'day': None, 'year': None}}, 'company': 'Oost NL', 'description': 'Supporting (international) companies to establish / expand business in East-Netherlands.', 'title': 'Team Manager Foreign Investments Health & Food', 'employment_type': 'Full-time'}, {'location': 'Apeldoorn Area, Netherlands', 'date': {'start': {'month': 4, 'day': None, 'year': 2018}, 'end': {'month': 1, 'day': None, 'year': 2019}}, 'company': 'Oost NL', 'description': None, 'title': 'Advisor Energy and Food', 'employment_type': None}]}, {'company': {'id': None, 'name': 'the world', 'logo': None, 'url': None, 'employees': {'start': None, 'end': None}}, 'date': {'start': {'month': 1, 'day': None, 'year': 2018}, 'end': {'month': 3, 'day': None, 'year': 2018}}, 'profile_positions': [{'location': None, 'date': {'start': {'month': 1, 'day': None, 'year': 2018}, 'end': {'month': 3, 'day': None, 'year': 2018}}, 'company': 'the world', 'description': 'Relocating to The Netherlands & Traveling', 'title': 'Short Sabbatical', 'employment_type': None}]}, {'company': {'id': 70562073, 'name': 'Embassy of the Kingdom of the Netherlands in Malaysia', 'logo': 'https://media.licdn.com/dms/image/C560BAQF8RhYrsEda2g/company-logo_400_400/0/1608517361111?e=1700697600&v=beta&t=5aUXVdzwJ5a3GlK2ZXdneBKiKkNF7VCit-8pPUDr-QY', 'url': 'https://www.linkedin.com/company/embassy-of-the-kingdom-of-the-netherlands-in-malaysia/', 'employees': {'start': 11, 'end': 50}}, 'date': {'start': {'month': 7, 'day': None, 'year': 2013}, 'end': {'month': 12, 'day': None, 'year': 2017}}, 'profile_positions': [{'location': 'Kuala Lumpur', 'date': {'start': {'month': 7, 'day': None, 'year': 2013}, 'end': {'month': 12, 'day': None, 'year': 2017}}, 'company': 'Embassy of the Kingdom of the Netherlands in Malaysia', 'description': 'Regional role, based in Singapore\n\nMain focus in Malaysia is Biobased Economy, adding value to waste streams and reducing environmental impact.', 'title': 'Innovation Advisor', 'employment_type': None}]}, {'company': {'id': 9450736, 'name': 'Embassy of the Kingdom of the Netherlands in Singapore', 'logo': 'https://media.licdn.com/dms/image/C4E0BAQGVCxWG_bKggA/company-logo_400_400/0/1519891312029?e=1700697600&v=beta&t=GZ6Rbgm465P8ypJuhHjFJTccY1QyfDRWx6bE9py-Xks', 'url': 'https://www.linkedin.com/company/nlinsingapore/', 'employees': {'start': 11, 'end': 50}}, 'date': {'start': {'month': 2, 'day': None, 'year': 2012}, 'end': {'month': 12, 'day': None, 'year': 2017}}, 'profile_positions': [{'location': 'Singapore', 'date': {'start': {'month': 2, 'day': None, 'year': 2012}, 'end': {'month': 12, 'day': None, 'year': 2017}}, 'company': 'Embassy of the Kingdom of the Netherlands in Singapore', 'description': 'The Holland Innovation Network (Innovatie Attaché Netwerk) supports the internationalization of Dutch R&D in the triple helix of government, companies and universities/research institutes. The Innovation Advisors are the liaison between science and technology landscapes in the Netherlands and Singapore.\nIncluding, but not limited to:\n- technology matchmaking (G2G, B2B, K2K, and all possible diagonal combinations)\n- information transfer.\n\nThe priority sectors for the Embassy of The Netherlands in Singapore are:\n- High Tech (key words: Smart Nation, Autonomous Vehicles, Robotics)\n- Life Sciences & Health (key words: Successful Ageing, Efficiency in Healthcare)\n- Energy & Environment (key words: Renewables, Circular Economy)\n- Water & Maritime (key words: Building with Nature, Green Shipping)', 'title': 'Head of Holland Innovation Network | Senior Innovatie Attache  | Senior Beleidsmedewerker', 'employment_type': None}]}, {'company': {'id': 1486, 'name': 'Merck Sharp & Dohme', 'logo': 'https://media.licdn.com/dms/image/D4E0BAQFlCZ01Dm-rvw/company-logo_400_400/0/1688564237290?e=1700697600&v=beta&t=_nPHfn3JQyhWKxdzRK6rysbLVUYDm-W5phzbQJ7FbXw', 'url': 'https://www.linkedin.com/company/merck/', 'employees': {'start': 10001, 'end': None}}, 'date': {'start': {'month': 11, 'day': None, 'year': 2009}, 'end': {'month': 12, 'day': None, 'year': 2011}}, 'profile_positions': [{'location': 'Singapore, Biopolis', 'date': {'start': {'month': 11, 'day': None, 'year': 2009}, 'end': {'month': 12, 'day': None, 'year': 2011}}, 'company': 'Merck', 'description': ""Accepted a severance package as part of Merck's overall workforce reduction plan in 2011.\n\t\t\t\t\t\nSupported building brand new translational medicine research laboratory.\n\nLiaising with authorities to set-up (Animal) BioSafety Level 2 laboratories, licensed for biological agents and toxins, and for genetically modified viruses/cells/animals.\n\nCoaching and training of new staff to work safely with blood borne pathogens in (pre) clinical tissue samples; cell culture techniques and in vivo techniques.\n\nScientist, Pharmacology\n- Cell-based techniques: flow cytometry for detection of intra- and extracellular biomarkers; whole-blood cell cultures to determine secreted biomarkers; neutralizing antibody detection assay;\n- Transferred methodology of in vivo genetic modification with adeno-associated viral vector in mice from US to Singapore; \n- Designed, established and validated xenograft models for collaboration with SBIC, and thereby contributing to development of translational state-of-the-art non-invasive imaging methods"", 'title': 'Scientist Pharmacology & Cell-Based Assays, Biosafety Officer', 'employment_type': None}]}, {'company': {'id': 2368, 'name': 'Schering-Plough Research Institute', 'logo': 'https://media.licdn.com/dms/image/C4E0BAQH8e7Se56iX5w/company-logo_400_400/0/1519856120438?e=1700697600&v=beta&t=5yhePzwqN9z1v2qAFHvBW_JeNYOiCI4JozS1arvW3Vs', 'url': 'https://www.linkedin.com/company/schering-plough-research-institute/', 'employees': {'start': 10001, 'end': None}}, 'date': {'start': {'month': 3, 'day': None, 'year': 2007}, 'end': {'month': 6, 'day': None, 'year': 2010}}, 'profile_positions': [{'location': None, 'date': {'start': {'month': 1, 'day': None, 'year': 2009}, 'end': {'month': 6, 'day': None, 'year': 2010}}, 'company': 'Schering-Plough Research Institute', 'description': 'Exciting relocation to Singapore as part of the pioneering team to setup the new Schering-Plough Translational Medicine Research Centre. Schering-Plough was acquired by MSD in 2010.', 'title': 'sr associate scientist', 'employment_type': None}, {'location': 'Oss, The Netherlands', 'date': {'start': {'month': 3, 'day': None, 'year': 2007}, 'end': {'month': 12, 'day': None, 'year': 2008}}, 'company': 'Schering-Plough Research Institute', 'description': 'Immuno-oncology project, pembrolizumab /keytruda (2007-2008)\nSupported cross-functional project teams and collaborations with research site in US, contract research organization, and university hospital.\n- Determined translational efficacy biomarkers for therapeutic antibody treatment in translational and clinical models;\nPresented and discussed the findings within the company and to external collaborators (medical doctors from university hospital); \nJoined team effort in coordination of successful preclinical study with aim to determine tolerability, pharmacokinetic and biomarker identification;\nSignificantly contributed to two filed patents and one submitted article and, importantly, transfer project into clinical phase.  \n\nOrganizational responsibilities: - Managed BSL-2; Coordinated shipment of chemical and biological samples; Supervised and trained co-workers and trainees.\n\nOncology biosimilar project (2006)\nEstablishment and validation of xenograft model in mice for oncology research; Developed anti-idiotypic ELISA; Revealed tumor morphology with immunohistochemistry; Report; Coached master trainee.', 'title': 'sr research assistant', 'employment_type': None}]}, {'company': {'id': 3603, 'name': 'Organon Pharmaceuticals', 'logo': None, 'url': 'https://www.linkedin.com/company/organon-pharmaceuticals/', 'employees': {'start': 1001, 'end': 5000}}, 'date': {'start': {'month': 3, 'day': None, 'year': 2002}, 'end': {'month': 3, 'day': None, 'year': 2007}}, 'profile_positions': [{'location': None, 'date': {'start': {'month': 3, 'day': None, 'year': 2002}, 'end': {'month': 3, 'day': None, 'year': 2007}}, 'company': 'Organon Pharmaceuticals', 'description': 'Cellular immunology projects (2006)\t\n- Setup and validation of a murine model for in vivo alloresponsive T cell proliferation, using flow cytometry and Luminex\n\nContraception project (2005) \n- Delivered proof of principle that GPCR antagonists inhibit follicular growth and ovulation, with the following techniques: HTS screening in CHO cells; in vivo (rat) models of folliculogenesis and ovulation inhibition; in vitro human granulosa cell assay\n\t\t\t\t\nG-Protein Coupled Receptors (2003-2004)\n- Investigated role of GPCR in hypothalamus-pituitary-ovary axis with in vivo (rat) models for folliculogenesis and ovulation induction \t\n\n\nNuclear Receptors (2002-2003)\n- Primary rat pituitary cell culture; -In vivo models (rat and guinea pig) for folliculogenesis; histology and ELISA.', 'title': 'research assistent', 'employment_type': None}]}, {'company': {'id': None, 'name': 'Solvay Pharmaceuticals, acquired by Abbott', 'logo': None, 'url': None, 'employees': {'start': None, 'end': None}}, 'date': {'start': {'month': 2, 'day': None, 'year': 2001}, 'end': {'month': 12, 'day': None, 'year': 2001}}, 'profile_positions': [{'location': None, 'date': {'start': {'month': 2, 'day': None, 'year': 2001}, 'end': {'month': 12, 'day': None, 'year': 2001}}, 'company': 'Solvay Pharmaceuticals, acquired by Abbott', 'description': 'Bachelors Trainee\nBehavioral Studies in CNS research \nmainly in antipsychotics study (2001)\n- Setup and validation of a prepulse inhibition test in mice', 'title': 'BSc Trainee', 'employment_type': None}]}]",[],"['Business Networking', 'International Business Development', 'Public-private Partnerships', 'Innovation Consulting', 'Matchmaking', 'Drug Discovery', 'Lifesciences', 'Immunology', 'Pharmacology', 'Translational Medicine', 'Oncology', 'New Business Development', 'Public Policy', 'Technological Innovation', 'Business Development']",,,
